Aurobindo again under FDA fire; Bureaucrats still trying to define "counterfeit;"

> The FDA wants a detailed action plan from Aurobindo Pharma for packaging and labeling compliance at its facility near Hyderabad in southern India. Story

> The World Health Assembly has decided it needs another year before it can make recommendations to fight drug counterfeiting; still problematic is the untangling of trade and intellectual property issues from counterfeiting. Article

> Pfizer says it will spend $21 million to upgrade sterile manufacturing ops at its Portage, MI, facility. Report

> Contract drug developer and manufacturer The Almac Group last week opened its new North American headquarters in Souderton, PA. Release

> Texas A&M University has stepped forward to become one of the U.S. centers for defense against infectious diseases and other biological threats. Item

> AstraZeneca says it's cutting 145 manufacturing jobs at its Westborough, MA, plant. Story

> India plans to announce details about whether the makers of patented drugs are meeting domestic demand at reasonable prices. News

> Nigeria has mandated that patent medicine dealers establish self-regulatory mechanisms for adherence to ethical standards. Article

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.